Skip to main content
GutCited

Saccharomyces boulardii para Antibiotic-Associated Diarrhea (AAD)

A

Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Conclusión

Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.

Key Study Findings

Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None vs: None Outcome: None Efecto: None None

Población: Pediatric population

Review
Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping …
Dose: None vs: None Outcome: None Efecto: None None

Población: scoping review of intestinal dysbiosis definition, symptoms, and probiotic adjuvant therapy in adults and children

Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None vs: None Outcome: Clinical guideline recommendations for pediatric GI Efecto: None None

Población: Pediatric patients with GI disorders

Observational Study n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None vs: None Outcome: Probiotic prescribing habits of Italian PCPs Efecto: L. rhamnosus GG used by 91.8% None

Población: Italian primary care pediatricians

Randomized Controlled Trial n=564 20 weeks Double-blind
High-dose Probiotic Mix of Lactobacillus spp., Bifidobacterium spp., Bacillus coagulans, and Saccharomyces boulardii to Prevent …
Dose: None vs: Placebo Outcome: Quality of life Efecto: None P < .001

Población: None

Review
Clostridioides difficile Infections: Prevention and Treatment Strategies.
Dose: None vs: None Outcome: C. difficile infection treatment outcomes Efecto: None None

Población: Patients with C. difficile infection

Key Statistics

25

Estudios

5000

Participantes

Positive

A

Calificación

Referenced Papers

Advances in experimental … 2019 17 citas
The American journal … 2018 46 citas
Journal of pediatric … 2016 233 citas
Digestive diseases (Basel, … 2016 37 citas
The Cochrane database … 2015 233 citas
Journal of clinical … 2015 35 citas
Journal of clinical … 2011 432 citas
Journal for specialists … 2010 22 citas
American journal of … 2010
European journal of … 2009 91 citas
Current opinion in … 2009 82 citas
Advances in biochemical … 2008 535 citas
American family physician 2008
The Journal of … 2007 265 citas
International journal of … 2000 181 citas
Clinical infectious diseases … 1998 346 citas

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosificaciones de uso común

general:
250-500 mg/day (equivalent to 5-10 billion CFU)
aadprevention:
500 mg/day (start with antibiotic, continue 7 days after)
cdiffprevention:
500 mg twice daily as adjunct to standard therapy
travelersdiarrhea:
250-500 mg/day starting 5 days before travel

Límite superior: Well-tolerated up to 1,000 mg/day in clinical trials

Dosificaciones estudiadas en la investigación

Dosificación Duración Efecto N
None -- Mixed --
None -- Positive --
None -- Positive --
None -- Mixed 279
None 20 weeks Positive 564
None -- Positive --
None 1 weeks Positive 47
Various probiotic interventions -- Positive --

Mejor momento para tomar: Can be taken with or without food; space 2 hours from antifungals

Safety & Side Effects

Efectos secundarios reportados

  • Mild gas and bloating
  • Rare: fungemia in critically ill patients with central venous catheters
  • Thirst (yeast may increase water requirements)
  • Very rare: potential environmental contamination risk in ICU settings

Interacciones conocidas

  • Antifungal medications (may kill S. boulardii, reducing effectiveness)
  • Monoamine oxidase inhibitors (S. boulardii contains tyramine)
  • Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)

Ingesta máxima tolerable: Well-tolerated up to 1,000 mg/day in clinical trials

Consulte siempre a su profesional de salud antes de comenzar cualquier suplemento.Siempre consulte a su profesional de salud antes de comenzar cualquier suplemento.

Frequently Asked Questions

Does Saccharomyces boulardii help with Antibiotic-Associated Diarrhea (AAD)?
Based on 25 studies with 5,000 participants, there is strong evidence from multiple clinical trials that Saccharomyces boulardii may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Saccharomyces boulardii should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 25 peer-reviewed studies with 5,000 total participants. The overall direction of effect is positive.

Related Evidence

Otros ingredientes para Antibiotic-Associated Diarrhea (AAD)

Saccharomyces boulardii para otras condiciones

Aviso legal FDA: Estas declaraciones no han sido evaluadas por la Food and Drug Administration. Los productos y la información en este sitio web no están destinados a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. Las calificaciones de evidencia presentadas se basan en nuestro análisis de investigación publicada revisada por pares y no constituyen consejo médico. Siempre consulte a su profesional de salud antes de comenzar cualquier régimen de suplementos.